Trial Profile
A Randomized, Open Label, Three-Treatment, Three-Period, Six-Sequence Crossover Study to Compare the Pharmacokinetics of CJ-30039 and Lipidil Supra and to Investigate Food-effect on Pharmacokinetics of CJ-30039
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2020
Price :
$35
*
At a glance
- Drugs CJ 30039 (Primary) ; Fenofibrate
- Indications Hypercholesterolaemia; Hyperlipidaemia; Hypertriglyceridaemia
- Focus Pharmacokinetics
- Sponsors CJ Corporation; HK inno.N
- 01 Aug 2012 Actual patient number (48) added as reported by ClinicalTrials.gov.
- 01 Aug 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.
- 01 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.